F10 and interstitial lung disease: Use of amiodarone was associated with a higher risk of incident ILD in patients who were treated with FXa inhibitors (0.38 vs 0.26 per 100 patient-years; HR, 1.41 [95% CI, 1.15-1.73]; P < .001), dabigatran (0.31 vs 0.18 per 100 patient-years; HR, 1.62 [95% CI, 1.12-2.35]; P = .01), or warfarin (0.28 vs 0.13 per 100 patient-years; HR, 1.97 [95% CI, 1.32-2.95]; P < .001).